SCHEMBL7746322

SCHEMBL7746322

C[SiH](C)OC(CCC(C)(C)C)Oc1ccc(C(=O)c2ccc(OC(CCC(C)(C)C)O[SiH](C)C)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 9/20 0.41
SRD5A2 P31213 2/20 0.38
PPARA Q07869 3/20 0.37
KMT2A Q03164 2/20 0.37
MAPK1 P28482 2/20 0.36
PPARG P37231 2/20 0.35
FABP2 P12104 1/20 0.35
SLC22A12 Q96S37 1/20 0.35
SLC2A1 P11166 1/20 0.35
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
ABCB11 O95342 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
ADRB3 P13945 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6705375 0.73 RIPK1 (0.36) KMT2AMEN1ACHE
SCHEMBL14723237 0.65 ELANE (0.58) ELANESRD5A2PPARAKMT2AMAPK1
SCHEMBL2517350 0.64 KMT2A (0.73) ELANESRD5A2KMT2AMAPK1LMNA
SCHEMBL8373045 0.64 ELANE (0.53) ELANESRD5A2PPARAKMT2AMAPK1
SCHEMBL1952125 0.63 KMT2A (0.59) SRD5A2KMT2AMAPK1TSHRALDH1A1
SCHEMBL23373088 0.63 PPARA (0.71) ELANEPPARAMAPK1PPARGLMNA
SCHEMBL10591230 0.63 ELANE (0.57) ELANESRD5A2KMT2AMAPK1LMNA
SCHEMBL7416905 0.62 GRN (0.33) KMT2AMEN1
SCHEMBL478510 0.62 KMT2A (0.63) SRD5A2KMT2AMAPK1MAPTTSHR
SCHEMBL10592798 0.62 ELANE (0.47) ELANESRD5A2KMT2AMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6262251-B1 PRODUCT ANCHORED SEQUENCIAL SYNTHESIS (PASS); AN ANCHOR GROUP ATTACHED TO THE 5' END OF THE GROWING OLIGONUCLEOTIDE PRODUCT ALLOWS THE COUPLED PRODUCT TO BE SEPARATED FROM UNREACTED STARTING MATERIALS PROLIGO LLC 2001-07-17 US disclosed
EP-0979233-A4 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES PROLIGO L L C (US) 2001-03-21 EP disclosed
EP-0979233-A1 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES NeXstar Pharmaceuticals, Inc. (US) 2000-02-16 EP disclosed
US-6001966-A REACTING N-TERMINAL PROTECTED AMINO ACID WITH PEPTIDE STARTING MATERIAL FORMING A PEPTIDE PRODUCT, PARTITIONING FROM UNREACTED MATERIAL AND REAGENTS BASED ON PRESENCE OF N-TERMINAL BLOCKING/ANCHORING GROUP PROLIGO LLC (US) 1999-12-14 US disclosed
US-5874532-A USING A N-TERMINAL PROTECTED AMINO ACID MONOMER NEXSTAR PHARMACEUTICALS, INC. (US) 1999-02-23 US disclosed
WO-1998047910-A1 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES PROLIGO LLC (US) 1998-10-29 WO disclosed